Skip to main content
Caplight Logo









Simmunome Inc.

Simmunome Inc.

Private
MontrealHealthcare & Life Scienceshttps://www.simmunome.com/

Last Round

Accelerator

Jun 20, 2025

Total Funding Raised

$1.89M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Simmunome Inc. is a biotechnology company that provides an AI-driven SaaS platform for disease simulations to predict clinical trial outcomes and improve drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Subscription SaaS

AI Layer

Application

Keywords

drug discoveryin silicobiological simulationbiotech AImulti-omicsclinical trial predictiontarget efficacypatient stratificationbiomarker discoverymechanistic modelingno-code SaaSprecision medicinetech-biodigital twinAI drug designcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Simmunome Inc. Comparables

Compare Simmunome Inc. with similar companies based on industry and business-model similarity.

Simmunome Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VeriSIM Life
86%
CytoReason
79%
Aitia
78%

Simmunome Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorJun 20, 2025
GrantFeb 28, 2025
Pre SeedSep 18, 2023
SAFEMar 7, 2023

Simmunome Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 115% MoM.

  • Jun 20, 2025

    $100K raised from Merck and CQDM.

Recent news

Latest coverage and updates

  • is_developingJul 7, 2026

    Simmunome Inc. is developing TME Predict on Jul 7th '26.

  • partners_withJul 7, 2026

    Simmunome Inc. partnered with MISO Chip Inc. on Jul 7th '26.

Simmunome Inc. Filings

Explore SEC and related filing metadata, where available.

Simmunome Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Simmunome Inc.'s valuation, stock price, and market status.

Is Simmunome Inc. a public or private company?

Simmunome Inc. is a private company.

What is the current stock price of Simmunome Inc.?

Simmunome Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Simmunome Inc. worth (valuation)?

Valuation information for Simmunome Inc. is not publicly available.

Can I buy Simmunome Inc. stock?

Simmunome Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Simmunome Inc.'s last funding round?

Simmunome Inc.'s most recent funding round was Accelerator on June 20, 2025.

Who are the main investors in Simmunome Inc.?

Key investors in Simmunome Inc. include Theodorus, Fonds d'investissement Eurêka.

Will Simmunome Inc. IPO soon?

No public IPO plans have been announced for Simmunome Inc..

How can I track Simmunome Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Simmunome Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMontreal
Employee Range5
Year Founded2018
Last FundingJun 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?